Alumis Q1 net loss $93.1M; Phase 3 envudeucitinib shows 68% PASI 90; NDA on track Q4 2026

ALUMIS INC.

2026-Q1 EPS reported -$0.74 revenue$1,741,000

Net loss $93.1M for Q1 2026; cash, equivalents and marketable securities $569.5M; runway into Q4 2027.
Phase 3 PsO: PASI 90 at Wk24: 68.0% and 62.1%; PASI 100: 41.0% and 39.5%; early quality-of-life improvements.
NDA submission for envudeucitinib in PsO on track Q4 2026; Phase 2b SLE topline data expected Q3 2026; TYK2 franchise update Q2 2026.
R&D expenses $81.5M (down from $96.6M); G&A $18.6M (down from $22.3M); exploring strategic alternatives for lonigutamab.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALUMIS INC. reported the quarter ended March 31, 2026 results: revenue $1.7 million, net income $93.1 million.

Period: the quarter ended March 31, 2026
Revenue: $1.7 million
Net income: $93.1 million
Result: reported results

Exact text from the filing

Quarter 2026 Financial Results ● As of March 31, 2026, Alumis had cash, cash equivalents and marketable securities of $569.5 million. ● Revenue included collaboration revenue of $1.7 million for the three months ended March 31, 2026, compared to license revenue of $17.4 million for the three months ended March 31, 2025, related to the collaboration and licensing

View on SEC.gov

Browse all earnings releases →

ALUMIS INC. filing history →

Source: SEC EDGAR

accession 0001847367-26-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.